There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H   (I)

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I):

##STR00001##

wherein A, D and Q are described herein.

Disclosed are compounds of general formulas I-III that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL. ##STR00001##

Disclosed are compounds of general formulas I-III that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL. ##STR00001##

The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same, wherein it has been identified that the lipid nanoparticle composed of the novel ionizable lipid exhibits an excellent rate of gene encapsulation efficiency and of gene delivery efficacy in in vitro/in vivo system and, simultaneously, exhibits an excellent rate of gene delivery efficacy even in serum-free environments, and thus the present invention can be effectively used as a composition for drug delivery.

The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same, wherein it has been identified that the lipid nanoparticle composed of the novel ionizable lipid exhibits an excellent rate of gene encapsulation efficiency and of gene delivery efficacy in in vitro/in vivo system and, simultaneously, exhibits an excellent rate of gene delivery efficacy even in serum-free environments, and thus the present invention can be effectively used as a composition for drug delivery.

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H  (I)

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H  (I)

The invention relates to primary para-phenylenediamine compounds substituted with an aliphatic chain comprising a cationic heterocyclic group according to formula (I), as well as the organic or mineral acid or base addition salts thereof, optical isomers, geometric isomers, tautomers, mesomers and/or solvates thereof, such as hydrates. Formula (I), wherein: ALK is a linear or branched, optionally substituted, alkylene chain comprising 3 to 8 carbon atoms; HET.sup.+ is a saturated or unsaturated, aromatic or non-aromatic cationic heterocyclic group, optionally substituted, comprising 5 to 0 links, optionally substituted, and comprising one or more ammonium groups; and An.sup.−, present or absent, is a mineral or organic anionic counterion ensuring the electroneutrality of the molecule. The present invention also relates to a composition comprising one or more of these previously defined compounds, in a medium suitable for dyeing. The present invention lastly relates to a dyeing device consisting of a first compartment which contains said composition, and a second compartment containing one or more oxidising agents.

##STR00001##

Substituted aromatic sulfonamides of formula (I) ##STR00001##
pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.